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OBJECTIVE: To estimate the annual cost of chronic
obstructive pulmonary disease (COPD) to the California
Medicaid (“Medi-Cal”) program. METHODS: This
study employed a retrospective matched cohort design
and administrative claims data for a 20% random sample
of Medi-Cal recipients. Patients selected were 50+ years
of age, with a diagnosis of COPD in 2000, and eligible
for Medicaid as of January 1, 2000. The comparison
cohort consisted of patients without COPD matched on
age, gender, race, and dual (Medicare/Medicaid) eligibil-
ity status. The cost of COPD was estimated as the dif-
ference in mean Medi-Cal payments between the COPD
and comparison cohorts during 2000. RESULTS: A total
of 12,538 patients with COPD met study inclusion crite-
ria. Approximately 8% were diagnosed with emphysema,
37% with chronic bronchitis, and 55% with unclassiﬁed
chronic airway obstruction. COPD patients and their
matched controls (n = 12,538) averaged 70 years of age;
55% were female, 55% were white, and 65% were 
eligible for Medicare beneﬁts. Charlson comorbidities,
especially congestive heart failure and vascular disease,
were more common in the COPD cohort. The proportion
of patients hospitalized was higher in the COPD cohort
both for respiratory-related conditions (19% vs. 2% for
controls, p < 0.05) and for any reason (38% vs. 15%, 
p < 0.05). The annual per-patient cost of COPD was 
estimated to be $3185 ($9537 for the COPD cohort
minus $6352 for the control cohort), 55% ($1765) of
which was due to hospitalizations. Annual per-patient
costs of COPD were $4679 for patients <65 years versus
$2322 for those 65+ years. Disease costs also were higher
among patients with emphysema ($7094) versus chronic
bronchitis ($3131) or unclassiﬁed chronic airway
obstruction ($2694). CONCLUSIONS: On an aggregate
basis, COPD costs the Medi-Cal program $200 million
annually. Acute hospitalizations drive costs, despite cov-
erage available through Medicare for the use of these ser-
vices by elderly patients.
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OBJECTIVES: According to National Cholesterol 
Education Program—Adult Treatment Panel III, baseline
lipid and lipoprotein measurements should be docu-
mented prior to initiating lipid-lowering therapy. This
study describes the patterns of nonconformance to the
measurement guideline, and assesses whether the non-
conformance is associated with emergency department or
hospital utilization. METHODS: Data were obtained
from an administrative database of a managed care orga-
nization. The study sample consisted of all continuously
eligible adult patients newly initiated with statins from
June 1998–June 2000. All patients were followed for one
year. Patients without lipid or lipoprotein measurement
within six months prior to or on initiation date were iden-
tiﬁed as nonconforming. CPT codes were used to identify
lipid/lipoprotein measurements. Cox proportional hazard
regression evaluated the impact of laboratory nonconfor-
mance to time to the ﬁrst emergency department or 
hospital utilization. Logistic regression was performed to
assess the risk factors for nonconformance. RESULTS:
Among 25,854 selected patients, 10,205 (39.5%) patients
have any claim record for lipid/lipoprotein measurement
before initiation of statin therapy. After controlling for 38
covariates including patient demographics, payer type,
physician specialty, previous drug, and medical utilization
pattern, and comorbidities, patients with nonconfor-
mance have 9.2% higher likelihood of earlier emergency
department or hospital utilization conforming patients 
(p = 0.006). Logistic regression revealed that older age,
HMO in contrast to PPO are risk factors of nonconfor-
mance, while prescribing physician specialty (cardiology
or internal medicine), previous use of Niacin, and patients
with comorbidities are more likely to receive baseline
measurement. CONCLUSIONS: The use of administra-
tive claims to determine conformance with ATP III on
lipid/lipoprotein measurement is subject to reporting lim-
itations, but it appears that recorded rate of conformance
to the guideline recommendation is low. Nonconfor-
mance to the guideline recommendation is signiﬁcantly
associated with emergency department or hospital 
utilization.
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OBJECTIVE: Clopidogrel is an antiplatelet agent that 
has been shown to reduce the risk of ischemic stroke 
(IS), myocardial infarction (MI), and vascular death
(“atherothrombotic events”) compared with aspirin in
patients with recent IS, recent MI, or symptomatic periph-
eral arterial disease (PAD). The objective of this study was
to estimate the cost-effectiveness of clopidogrel versus
aspirin in these patients. METHODS: We developed a
Markov model in which patients with recent 
IS, recent MI, or PAD were assumed to receive lifelong
therapy with clopidogrel or aspirin. Reduction in risk of
atherothrombotic events for clopidogrel (vs aspirin) was
estimated using data from the Clopidogrel versus Aspirin
in Patients at Risk of Ischemic Events (CAPRIE) clinical
trial. Costs considered in the model included those of
